May 24, 2005 |
Researchers reported yesterday that more people suffered serious side effects from the cholesterol drug Crestor than from other drugs, and recommended that millions of people use it only as a last resort. The Tufts University study contradicted findings by the U.S. Food and Drug Administration and will not help Crestor's maker, AstraZeneca P.L.C. - with U.S. operations in Wilmington - build Crestor into the blockbuster product it has intended. Crestor was the first cholesterol-lowering drug in a class known as statins to be introduced since Baycol was withdrawn in 2001 because of muscle problems called rhabdomyolysis.
September 2, 2011 |
Drugmaker AstraZeneca PLC's big gamble, an attempt to prove its top-selling drug works better than rival cholesterol blockbuster Lipitor, appears to have backfired. A study meant to show AstraZeneca's cholesterol drug Crestor prevents plaque buildup in heart arteries better than Pfizer Inc.'s Lipitor showed no clear advantage for Crestor. Two generic versions of Lipitor, the world's top-selling drug for several years, are expected to hit the U.S. market on Nov. 30. Analysts wrote Friday that the study result will make it hard for the British drugmaker to argue patients would fare better on its Crestor than on much-cheaper generic versions of Lipitor.
July 1, 2010 |
A federal judge in Delaware turned down attempts by Israeli-owned Teva Pharmaceuticals USA , of North Wales, and seven other makers of generic drugs to break Anglo-Swedish drugmaker AstraZeneca P.L.C.'s patent on the anticholesterol drug Crestor . AstraZeneca said the ruling by federal Judge Joseph J. Farnan Jr. would stop the U.S. Food and Drug Administration from approving knockoffs of Crestor before the patent expires in 2016. The company employs about 4,000 at its U.S. headquarters in Fairfax, Del. This is bad news for makers of cheap drugs and bargain-hunting, fat-afflicted consumers, but good news for AstraZeneca as it struggles to keep sales high before its most popular drugs face price competition.
August 4, 2004 |
The consumer group Public Citizen asked U.S. regulators yesterday for a criminal investigation of AstraZeneca P.L.C., alleging the drugmaker delayed reporting 23 cases of serious side effects in people taking its cholesterol-lowering medicine, Crestor. The advocacy group founded by Ralph Nader wants the Food and Drug Administration to remove Crestor from the market, contending the drug has been linked to kidney failure and potentially life-threatening muscle damage. Sidney M. Wolfe, director of Public Citizen's Health Research Group, said, in a letter to the FDA, AstraZeneca delayed reporting 19 cases of muscle weakening, or rhabdomyolysis, and four incidents of kidney damage.
March 15, 2005 |
The Food and Drug Administration said yesterday that the cholesterol drug Crestor is just as safe as other drugs in its class if used correctly, formally rebuffing a consumer recall drive and an FDA whistle-blower. However, several equity analysts expressed doubt that the FDA ruling would enable Crestor to reach the 20 percent market share its maker, AstraZeneca P.L.C., has sought. The drug is prescribed to just 4 percent of cholesterol-drug users after three years on the market.
September 3, 2011 |
Drugmaker AstraZeneca P.L.C.'s big gamble, an attempt to prove that its top-selling drug works better than rival cholesterol blockbuster Lipitor, appears to have backfired. A study meant to show AstraZeneca's cholesterol drug Crestor prevents plaque buildup in heart arteries better than Pfizer Inc.'s Lipitor showed no clear advantage for Crestor. AstraZeneca released preliminary results of the study Friday. Two generic versions of Lipitor, the world's top-selling drug for several years, are expected to hit the U.S. market Nov. 30. Analysts said the results would make it hard for AstraZeneca to argue patients would fare better on its Crestor than on much-cheaper generic versions of Lipitor.
June 28, 2001 |
AstraZeneca P.L.C., the British company with U.S. headquarters in Wilmington, said yesterday it submitted a formal application to the U.S. Food and Drug Administration for approval to sell its new cholesterol medication Crestor. Analysts expect Crestor to become a blockbuster drug with annual sales of between $2 billion and $4 billion by 2005. "This clearly is potentially a star in our portfolio of products," said David R. Brennan, AstraZeneca's senior vice president of commercial operations in the United States.
October 24, 2003 |
AstraZeneca P.L.C. beat analysts' earnings estimates yesterday with a 19 percent increase in third-quarter profit helped by a weaker dollar and several new medicines. AstraZeneca's earnings rose for the first time in five quarters, based on higher sales of its ulcer drug Nexium, which doubled in the quarter, and the introduction of new drugs Iressa for cancer and Crestor for cholesterol. The London-based drugmaker employs 5,000 at its U.S. headquarters and research complex near Wilmington.
July 23, 2004 |
AstraZeneca P.L.C., Europe's second-largest drugmaker, said second-quarter profit increased 25 percent as the company sold more of its ulcer-treatment Nexium and its schizophrenia drug Seroquel. The London-based company said net income was $833 million, or 50 cents a share, compared with $666 million, or 39 cents a share, in the same quarter a year ago. Revenue in the second-quarter rose 19 percent to $5.29 billion. A favorable currency exchange boosted sales by 8 percent.
April 29, 2005 |
AstraZeneca P.L.C., Europe's third-largest drugmaker, with U.S. operations based in Wilmington, rebounded from a tough year to post a 31 percent rise in first-quarter profit, it said yesterday. The London company raised worldwide sales by 13 percent, to $5.74 billion, led by top-selling heartburn drug Nexium. It held marketing, sales, administration and research costs essentially flat. "This excellent start to the year has set us on track to deliver our financial targets for the year," said Sir Tom McKillop, the chief executive officer who delayed retirement following last year's setbacks on the cancer treatment Iressa, cholesterol drug Crestor, and blood-thinner Exanta.